Notice2024-08013
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
April 16, 2024
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 74 (Tuesday, April 16, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 74 (Tuesday, April 16, 2024)]
[Notices]
[Page 26900]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-08013]
[[Page 26900]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Dawn Taylor-Mulneix at 301-767-5189,
or <a href="/cdn-cgi/l/email-protection#c0a4a1b7aeeeb4a1b9acafb2edadb5acaea5a9b880aea9a8eea7afb6"><span class="__cf_email__" data-cfemail="d5b1b4a2bbfba1b4acb9baa7f8b8a0b9bbb0bcad95bbbcbdfbb2baa3">[email protected]</span></a>. Licensing information may be obtained
by communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852: tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Human Monoclonal Antibodies That Target Plasmodium Falciparum
Sporozoites
Description of Technology
Malaria is one of the world's deadliest infectious diseases,
causing an estimated 249 million cases and 608,000 deaths annually,
with children in the regions of Africa and South Asia being most
vulnerable. Approx 2,000 cases of malaria are reported in the United
States each year, by travelers from malaria-risk countries. Malaria is
a mosquito-borne parasitic disease transmitted through the bite of
infected female mosquitoes, which introduces Plasmodium sporozoites
into the bloodstream of the human host. There are five Plasmodium
parasite species that cause malaria in humans, of which, the vast
majority of life-threatening cases are caused by infection with
Plasmodium falciparum parasites.
Researchers at NIAID have developed 11 human monoclonal antibodies
that bind to a unique site on the circumsporozoite protein (CSP) on
Plasmodium falciparum sporozoites that is not targeted by any known
monoclonal antibodies. These antibodies do not bind to recombinant
forms of CSP and as such bind to a processed or post-translational form
of the protein processed by the sporozoites. In vivo studies have shown
several of these antibodies can substantially reduce liver parasite
burden in a mouse model of malaria. These antibodies can work
cooperatively with known antibodies that target the repeat region of
CSP. Some of these novel antibodies have shown enhanced protection in
an animal model when combined with known protective monoclonal
antibodies against sporozoites, suggesting that together they may form
an effective cocktail to prevent malaria.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications
<bullet> Prophylactic and preventative treatment against malaria.
Competitive Advantages
<bullet> These antibodies bind to a unique site on the
circumsporozoite protein (CSP) on Plasmodium falciparum sporozoites
that is distinct from the targets of pre-existing mAbs.
<bullet> These monoclonal antibodies can be used alone or in
combination with existing antibodies.
Development Stage
<bullet> Pre-Clinical
Inventors: Joshua Tan, Ph.D., Cherrelle Dacon, Ph.D., both of
NIAID.
Publications: n/a.
Intellectual Property: HHS Reference No. E-212-2022-0. U.S.
Provisional Patent Application No. 63/409,016, filed on September 22,
2022, and PCT Patent Application No. PCT/US2023/074791, filed on
September 21, 2023.
Licensing Contact: To license this technology, please contact Dawn
Taylor-Mulneix at 301-767-5189, or <a href="/cdn-cgi/l/email-protection#3f5b5e4851114b5e4653504d12524a53515a56477f51565711585049"><span class="__cf_email__" data-cfemail="9efaffe9f0b0eaffe7f2f1ecb3f3ebf2f0fbf7e6def0f7f6b0f9f1e8">[email protected]</span></a>, and
reference E-212-2022.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this technology. Areas of specific
interest include (a) testing developability of these antibodies (e.g.,
biophysical characteristics, cross-reactivity, pharmacokinetics,
toxicity), (b) pre-clinical model assessment, and (c) human clinical
trials. For collaboration opportunities, please contact Dawn Taylor-
Mulneix at 301-767-5189, or <a href="/cdn-cgi/l/email-protection#0d696c7a6323796c7461627f20607861636864754d636465236a627b"><span class="__cf_email__" data-cfemail="244045534a0a50455d484b56094951484a414d5c644a4d4c0a434b52">[email protected]</span></a>.
Dated: April 8, 2024.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2024-08013 Filed 4-15-24; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on April 16, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.